SLC28A1 inhibits clear cell renal cell carcinoma progression by affecting arachidonic acid metabolism: A novel nucleoside transporter-based targeted therapy strategy - PubMed
16 hours ago
- #targeted therapy
- #SLC28A1
- #ccRCC
- SLC28A1 identified as a key nucleoside transporter (NT) affecting prognosis in clear cell renal cell carcinoma (ccRCC).
- SLC28A1 inhibits ccRCC cell proliferation, migration, and invasion, and promotes ferroptosis via arachidonic acid metabolism regulated by the MAPK pathway and PLA2G12A.
- Sapitinib was screened as a small molecule drug binding to SLC28A1, with efficacy enhanced by targeted nanoparticle delivery, showing tumor inhibition in vitro and in vivo.
- A prognostic nomogram incorporating a risk scoring model based on NTs and clinicopathological factors was developed for ccRCC management.